Expression of Vascular Endothelial Growth Factor in Canine Inflammatory and Non-inflammatory Mammary Carcinoma

被引:43
作者
Millanta, F. [1 ]
Caneschi, V. [1 ]
Ressel, L. [1 ]
Citi, S. [2 ]
Poli, A. [1 ]
机构
[1] Univ Pisa, Sch Vet Med, Dept Anim Pathol, I-56100 Pisa, Italy
[2] Univ Pisa, Sch Vet Med, Dept Vet Clin Med, I-56100 Pisa, Italy
关键词
dog; HER-2; inflammatory mammary carcinoma; mammary tumours; steroid receptor; VEGF; BREAST-CANCER; PROGNOSTIC-FACTORS; HER-2; OVEREXPRESSION; METASTASIS; ESTROGEN; THERAPY; VEGF;
D O I
10.1016/j.jcpa.2009.06.004
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Inflammatory mammary carcinoma (IMC) is the most aggressive type of mammary tumour in the dog and has been proposed as a model for human inflammatory breast cancer. The aim of this study was to investigate angiogenesis in canine IMC by immunohistochemical assessment of the expression of vascular endothelial growth factor (VEGF). Tissues from 19 cases of IMC were compared with tissues from 27 cases of invasive mammary carcinoma without inflammation (non-IMC). Immunohistochemical expression of oestrogen receptor (ER), progesterone receptor (PR) and HER-2 receptor was also assessed. VEGF was strongly expressed in all IMCs and the percentage of VEGF-immunoreactive tumour cells was significantly higher in IMC than in non-IMC (P=0.02). There was no difference in HER-2 receptor expression between IMC and non-IMC, and no IMC expressed ER or PR. These results suggest that VEGF may contribute to the high angiogenic phenotype of canine IMC and that this expression may underlie the tendency towards local and systemic metastasis of these tumours. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 37 条
  • [1] Inflammatory mammary carcinoma in dogs:: 33 cases (1995-1999)
    Alenza, MDP
    Tabanera, E
    Peña, L
    [J]. JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2001, 219 (08): : 1110 - 1114
  • [2] Inflammatory breast carcinoma
    Chambler, AFW
    Drew, PJ
    Hill, ADK
    Darzi, A
    Monson, JRT
    [J]. SURGICAL ONCOLOGY-OXFORD, 1995, 4 (05): : 245 - 254
  • [3] CHEVALLIER B, 1987, CANCER-AM CANCER SOC, V60, P897, DOI 10.1002/1097-0142(19870815)60:4<897::AID-CNCR2820600430>3.0.CO
  • [4] 2-S
  • [5] de las Mulas JM, 2003, BREAST CANCER RES TR, V80, P363, DOI 10.1023/A:1024929730165
  • [6] PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP
    ELSTON, CW
    ELLIS, IO
    [J]. HISTOPATHOLOGY, 1991, 19 (05) : 403 - 410
  • [7] Molecular and biological properties of vascular endothelial growth factor
    Ferrara, N
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (07): : 527 - 543
  • [8] FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
  • [9] Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs
    Fox, Stephen B.
    Gasparini, Giampietro
    Harris, Adrian L.
    [J]. LANCET ONCOLOGY, 2001, 2 (05) : 278 - 289
  • [10] WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
    Kleer, CG
    Zhang, YH
    Pan, QT
    Gallagher, G
    Wu, M
    Wu, ZF
    Merajver, SD
    [J]. BREAST CANCER RESEARCH, 2004, 6 (02): : R110 - R115